Tuesday 19 March 2024
 
»
Tag
 
»
Drug companies

$1-5bn seen optimal for biotech M&A

Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough environment, Ernst & Young said. Big pharma companies are

Moreā€¦
 1 2 3 4 5 >  Last ›

calendarCalendar of Events

Ads